EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.81) by 4.29 percent. This is a 46.55 percent decrease over losses of $(0.58) per share from the same period last year. The company reported quarterly sales of $5.333 million which missed the analyst consensus estimate of $6.627 million by 19.52 percent. This is a 43.73 percent decrease over sales of $9.477 million the same period last year.